Nona Biosciences and GeneQuantum Healthcare Forge Strategic Alliance to Enhance Early Discovery of Next-Generation Bioconjugates

Nona Biosciences, a global leader in technology innovation and antibody discovery and development solutions, has recently announced a strategic partnership with GeneQuantum Healthcare. The collaboration aims to advance the early discovery of next-generation bioconjugates, combining Nona Biosciences' Harbour Mice® platform and advanced technologies with GeneQuantum's exclusive iLDC (intelligent Ligase-dependent Conjugation) and iGDC (intelligent Glycotransferase-dependent conjugation) platforms.

The partnership will synergize the strengths of both companies to enhance technology platform capabilities, providing a comprehensive solution for global partners engaged in the early discovery of next-generation bioconjugates.

Nona Biosciences, expressed enthusiasm about the collaboration, stating, "Leveraging our cutting-edge antibody technologies and extensive experience in antibody research and development, Nona is committed to providing innovative, diverse, and customized solutions for preclinical drug development. We look forward to collaborating with GeneQuantum Healthcare to continuously enhance the capabilities of innovative bioconjugate drug research and development, empowering global partners to advance their ADC drug R&D initiatives."

GeneQuantum Healthcare's Founder and Chairman, Gang Qin, PhD, highlighted the significance of their core technologies, iLDC and iGDC platforms, in addressing challenges prevalent in the ADC field. He emphasized the technologies' ability to reduce production costs, improve drug quality, and enhance global accessibility to ADC drugs. Qin expressed honor in collaborating with Nona Biosciences, stating, "By leveraging GeneQuantum's conjugation technology and Nona's extensive drug development experience, we believe that this collaboration will substantially improve high-quality and high-throughput screening for the early discovery of ADC drugs."

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!